NewsEarningsBajaj Healthcare Q3FY26 Results: Revenue Surges 31% YoY to ₹16,122 Crores, Net Profit Up 7.6%Bajaj Healthcare Q3FY26 Results: Revenue Surges 31% YoY to ₹16,122 Crores, Net Profit Up 7.6%
Bajaj Healthcare Limited reported impressive Q3FY26 results with revenue from operations growing 31.3% YoY to ₹16,122.27 crores and net profit increasing 7.6% to ₹1,567.38 crores. Nine-month revenue reached ₹45,797.39 crores, up 18.0% from the previous year. The Board approved reappointment of key executives including Chairman & Managing Director Sajankumar Rameshwarlal Bajaj and Managing Director Anil Champalal Jain for three-year terms starting April 2026, subject to shareholder approval.
*this image is generated using AI for illustrative purposes only.
Bajaj Healthcare Limited delivered strong financial performance in Q3FY26, with the pharmaceutical company reporting significant growth across key metrics for the quarter ended December 31, 2025.
Strong Revenue Growth Drives Q3FY26 Performance
The company's revenue from operations surged 31.3% year-on-year to ₹16,122.27 crores in Q3FY26, compared to ₹12,279.40 crores in the corresponding quarter of the previous year. This represents a sequential growth of 9.0% from Q2FY26's revenue of ₹14,791.49 crores.
| Financial Metric | Q3FY26 | Q3FY25 | YoY Growth (%) |
|---|---|---|---|
| Revenue from Operations | ₹16,122.27 cr | ₹12,279.40 cr | +31.3% |
| Total Income | ₹16,286.98 cr | ₹12,516.59 cr | +30.1% |
| Net Profit | ₹1,567.38 cr | ₹1,172.12 cr | +7.6% |
| Basic EPS | ₹4.96 | ₹3.65 | +35.9% |
Nine-Month Performance Shows Consistent Growth
For the nine-month period ended December 31, 2025, Bajaj Healthcare maintained its growth trajectory with revenue from operations reaching ₹45,797.39 crores, representing an 18.0% increase from ₹38,812.99 crores in the corresponding period of FY25. Net profit for the nine-month period stood at ₹3,861.67 crores, up 36.4% from ₹2,831.77 crores in the previous year.
Operational Efficiency and Cost Management
The company's total expenses for Q3FY26 increased to ₹14,362.52 crores from ₹11,351.30 crores in Q3FY25. Key expense components included cost of materials consumed at ₹6,940.90 crores and other expenses at ₹3,425.87 crores. Despite higher expenses, the company maintained healthy profit margins with profit before tax reaching ₹1,924.46 crores, up 65.1% year-on-year.
Board Approves Key Leadership Reappointments
The Board of Directors approved several important reappointments during their meeting held on January 16, 2026:
| Position | Name | Term Period | Status |
|---|---|---|---|
| Chairman & Managing Director | Sajankumar Rameshwarlal Bajaj | April 1, 2026 - March 31, 2029 | Subject to shareholder approval |
| Managing Director | Anil Champalal Jain | April 1, 2026 - March 31, 2029 | Subject to shareholder approval |
| Whole-Time Director | Namrata Sajankumar Bajaj | April 1, 2026 - March 31, 2029 | Subject to shareholder approval |
| Whole-Time Director | Pakshal Anil Jain | June 30, 2026 - June 29, 2029 | Subject to shareholder approval |
The reappointments reflect the board's confidence in the existing leadership team's ability to drive continued growth and operational excellence.
Discontinued Operations and Strategic Focus
The company reported a loss of ₹42.71 crores from discontinued operations in Q3FY26, compared to a loss of ₹324.44 crores in Q3FY25. These discontinued operations relate to certain manufacturing units and land parcels that the company has classified as held for sale under its strategic restructuring initiatives.
Strong Earnings Per Share Performance
Basic earnings per share from total operations improved significantly to ₹4.96 in Q3FY26 from ₹3.65 in Q3FY25, representing a 35.9% increase. For continuing operations alone, basic EPS stood at ₹5.10 compared to ₹4.66 in the previous year quarter.
Historical Stock Returns for Bajaj HealthCare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.77% | -4.48% | -5.30% | -23.77% | -28.24% | +7.76% |
20
